[CAS NO. 327613-57-0] BIO5192
PRODUCTS SPECIFICATIONS [327613-57-0]
DESCRIPTION [327613-57-0]
Overview
| MDL | MFCD26408178 |
|---|---|
| Molecular Weight | 817.78 |
| Molecular Formula | C38H46Cl2N6O8S |
| SMILES | O=[S](N(CCC1)[C@@H]1C(N[C@H](C(O)=O)CCNC([C@H](CC(C)C)N(C)C(CC(C=C2)=CC=C2NC(NC(C=CC=C3)=C3C)=O)=O)=O)=O)(C4=CC(Cl)=CC(Cl)=C4)=O |
Summary
IC50 & Target
|
α4β1 1.8 nM (IC 50 ) |
α9β1 138 nM (IC 50 ) |
α2β1 1053 nM (IC 50 ) |
α4β7 >500 nM (IC 50 ) |
In Vivo
The combination of BIO5192 (1 mg/kg; i.v.) and Plerixafor (5 mg/kg; s.c.) exert an additive effect on progenitor mobilization
[1]
.
BIO5192 (30 mg/kg; s.c; bid; during days 5 through 14) delays paralysis associated with EAE (experimental autoimmune encephalomyelitis)
[2]
.
BIO5192 (1 mg/kg, i.v.) shows the terminal half-life is 1.1 hours. BIO5192 (3, 10, and 30 mg/kg; s.c.) shows half-lives of 1.7, 2.7, and 4.7 hours, respectively. The blood plasma curves show that the AUC for the s.c. route of administration increased about 2.5-fold from 5,460 h*ng/ml for the 3 mg/kg dose to 14,175 h*ng/ml for the 30 mg/kg
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6J x 129Sv/J F1 mice [1] |
| Dosage: | 1 mg/kg (with Plerixafor: 5 mg/kg) |
| Administration: | I.v. |
| Result: | Exerted an additive effect on progenitor mobilization. |
| Animal Model: | Healthy female Lewis rats weighing 150g [2] |
| Dosage: | 30 mg/kg |
| Administration: | S.c; bid; during days 5 through 14 |
| Result: | Showed a 3-day delay in onset of disease. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 12.5 mg/mL ( 15.29 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2228 mL | 6.1141 mL | 12.2282 mL |
| 5 mM | 0.2446 mL | 1.2228 mL | 2.4456 mL |
| 10 mM | 0.1223 mL | 0.6114 mL | 1.2228 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1.25 mg/mL (1.53 mM); Clear solution
References
- [1] Ramirez P, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 2009;114(7):1340‐1343.
- [2] Leone DR, et al. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2003;305(3):
